ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2018
Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of Obesity on Durable Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.Artificial organs · 2026Pooled it
- Psychosocial Risk and Recurrent Hospitalizations in Women and Men Following LVAD Implantation: A Multi-State Analysis of the INTERMACS Registry.Journal of cardiovascular development and disease · 2025Article
- Infections in Patients with Mechanical Circulatory Support.Infectious disease clinics of North America · 2024Review
- Incomplete Data and Potential Risks of Drugs in People with Obesity.Current obesity reports · 2023Review
- Cardiac Cachexia in Left Ventricular Assist Device Recipients and the Implications of Weight Gain Early After Implantation.Journal of the American Heart Association · 2023Article
- Left Ventricular Assist Device as a Destination Therapy: Current Situation and the Importance of Patient Selection.Life (Basel, Switzerland) · 2023Review
- How does age affect outcomes after left ventricular assist device implantation: results from the PCHF-VAD registry.ESC heart failure · 2023Article
- The Impact of Obesity on T and NK Cells after LVAD Implantation.Obesity facts · 2023Article
- Left Ventricular Assist Devices: A Primer For the General Cardiologist.Journal of the American Heart Association · 2022Review
- Sex Differences in Recovery and Device Replacement After Left Ventricular Assist Device Implantation as Destination Therapy.Journal of the American Heart Association · 2022Article
- Post-operative infection in mechanical circulatory support patients.Annals of translational medicine · 2020Review
- Left ventricular assist devices as destination therapy in stage D heart failure.Journal of geriatric cardiology : JGC · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundLimited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry.
methodsPatients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m
resultsBetween 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026).
conclusionsAlthough BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.